| 纯度 | >90%SDS-PAGE. |
| 种属 | Vibrio |
| 靶点 | ctxB |
| Uniprot No | P01556 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-124aa |
| 氨基酸序列 | TPQNITDLCAEYHNTQIYTLNDKIFSYTESLAGKREMAIITFKNGAIFQVEVPGSQHIDSQKKAIERMKDTLRIAYLTEAKVEKLCVWNNKTPHAIAAISMAN |
| 预测分子量 | 15.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ctxB重组蛋白的模拟参考文献示例(非真实文献，仅供格式参考)：
1. **文献名称**：*Expression and Purification of Recombinant Cholera Toxin B Subunit in Escherichia coli*
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌表达系统高效表达霍乱毒素B亚基(ctxB)重组蛋白，优化了纯化条件并验证了其与GM1神经节苷脂受体的结合活性。
2. **文献名称**：*Structural Analysis of ctxB Recombinant Protein for Vaccine Development*
**作者**：Lee C, et al.
**摘要**：利用X射线晶体学解析了重组ctxB蛋白的三维结构，揭示了其五聚体稳定性机制，为基于ctxB的疫苗载体设计提供结构基础。
3. **文献名称**：*Immunogenicity of Plant-Derived ctxB Fusion Protein in Murine Models*
**作者**：Wang Y, et al.
**摘要**：通过植物表达系统生产ctxB融合蛋白，在小鼠模型中证明其可诱导黏膜免疫应答，为口服疫苗开发提供新策略。
4. **文献名称**：*Enhancing Adjuvant Activity of ctxB through Site-Directed Mutagenesis*
**作者**：Rodriguez M, et al.
**摘要**：通过定点突变改造重组ctxB蛋白，提高了其免疫佐剂效应，并评估了突变体在递送抗原肽中的应用潜力。
---
建议通过PubMed、Google Scholar等平台搜索关键词"cholera toxin B subunit recombinant"或"ctxB expression"获取真实文献。
**Background of CTxB Recombinant Protein**
Cholera toxin B subunit (CTxB) is a non-toxic component of the cholera toxin produced by *Vibrio cholerae*, the bacterium responsible for cholera. The holotoxin comprises a pentameric B subunit (CTxB) and a catalytic A subunit (CTxA). CTxB mediates toxin binding to host cells by targeting GM1 gangliosides on cell membranes, facilitating the entry of CTxA, which induces severe diarrhea. Recombinant CTxB, produced via genetic engineering in heterologous systems like *E. coli*, retains GM1-binding capacity but lacks the toxic CTxA moiety, making it a safe tool for research and therapeutic applications.
CTxB’s unique properties have driven its use in vaccines, immunology, and cell biology. As a potent mucosal adjuvant, it enhances immune responses to co-administered antigens, particularly in oral vaccines. Its ability to bind GM1 also enables studies on lipid raft dynamics, intracellular trafficking, and antigen presentation. Additionally, CTxB serves as a carrier for drug delivery or antigen conjugation due to its stability and specific targeting.
In vaccine development, CTxB is a key component of Dukoral®, a WHO-prequalified cholera vaccine, where it elicits protective antibodies against cholera. Beyond infectious diseases, CTxB is explored in autoimmune and cancer therapies, leveraging its immunomodulatory functions. Its recombinant production ensures scalability and purity, critical for clinical and industrial use.
Overall, CTxB recombinant protein bridges microbiology and biotechnology, offering versatile applications in science and medicine.
×
